NIH Alzheimer’s Initiative To Promote Neuroimaging, Identify Biomarkers
This article was originally published in The Pink Sheet Daily
Program aimed at speeding Alzheimer’s drug development through neuroimaging and biomarkers is launched by the National Institute on Aging through a five-year, $60 mil. project. Large pharma companies are contributing funds to a multi-site study of 800 subjects.
You may also be interested in...
VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.
A National Institutes of Health review has found only a small number of consulting relationships between researchers and pharmaceutical companies, NIH Deputy Director Kington says. The new policy must be approved by the White House.
FDA action to emphasize the risks of prescribing antidepressant drugs to children and adolescents would endanger minors with depression and run counter to the evidence emerging from a National Institute of Mental Health study, NIMH Director Insel says.